William Song

Dr. William Song


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2017 in Medical Physics
Verified
Journal Article
Closed access
PDF file
HSHabib Safigholi
Habib Safigholi
DHDae Yup Han
Dae Yup Han
SMShahram Mashouf
Shahram Mashouf
ASAbraam Soliman
Abraam Soliman
AMAli S. Meigooni
Ali S. Meigooni
WSWilliam Song
William Song

22 November 2021 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
WSWilliam Song
William Song
JRJames L Robar
James L Robar
BMBjörn Morén
Björn Morén
TLTorbjörn Larsson
Torbjörn Larsson
ÅTÅsa Carlsson Tedgren
Åsa Carlsson Tedgren
XJXun Jia
Xun Jia
Brachytherapy is a mature treatment modality. The literature is abundant in terms of review articles and comprehensive books on the latest established as well as evolving clinical practices. The intent of this article is to part ways and look beyond the current state-of-the-art and review emerging technologies that are noteworthy and perhaps may drive the future innovations in the field. There are plenty of candidate topics that deserve a deeper look, of course, but with practical limits in this communicative platform, we explore four topics that perhaps is worthwhile to review in detail at this time. First, intensity modulated brachytherapy (IMBT) is reviewed. The IMBT takes advantage of anisotropic radiation profile generated through intelligent high-density shielding designs incorporated onto sources and applicators such to achieve high quality plans. Second, emerging applications of 3D printing (i.e. additive manufacturing) in brachytherapy are reviewed. With the advent of 3D printing, interest in this technology in brachytherapy has been immense and translation swift due to their potential to tailor applicators and treatments customizable to each individual patient. This is followed by, in third, innovations in treatment planning concerning catheter placement and dwell times where new modelling approaches, solution algorithms, and technological advances are reviewed. And, fourth and lastly, applications of a new machine learning technique, called deep learning, which has the potential to improve and automate all aspects of brachytherapy workflow, are reviewed. We do not expect that all ideas and innovations reviewed in this article will ultimately reach clinic but, nonetheless, this review provides a decent glimpse of what is to come. It would be exciting to monitor as IMBT, 3D printing, novel optimization algorithms, and deep learning technologies evolve over time and translate into pilot testing and sensibly phased clinical trials, and ultimately make a difference for cancer patients. Today’s fancy is tomorrow’s reality. The future is bright for brachytherapy.

6 December 2024 in Brachytherapy
Verified
Journal Article
Closed access
SGSuman Gautam
Suman Gautam
EFEmily Flower
Emily Flower
DRDylan Richeson
Dylan Richeson
ISIkchit Sangha
Ikchit Sangha
TMTianjun Ma
Tianjun Ma
WSWilliam Song
William Song

26 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJames J. Sohn
James J. Sohn
MPMitchell Polizzi
Mitchell Polizzi
DRDylan Richeson
Dylan Richeson
SGSomayeh Gholami
Somayeh Gholami
Indra J DasIndra J Das
Indra J Das
WSWilliam Song
William Song
A novel clinical workflow utilizing a direction modulated brachytherapy (DMBT) tandem applicator in combination with a patient-specific, 3D printed vaginal needle-track template for an advanced image-guided adaptive interstitial brachytherapy of the cervix. The proposed workflow has three main steps: (1) pre-treatment MRI, (2) an initial optimization of the needle positions based on the DMBT tandem positioning and patient anatomy, and a subsequent inverse optimization using the combined DMBT tandem and needles, and (3) rapid 3D printing. We retrospectively re-planned five patient cases for two scenarios; one plan with the DMBT tandem (T) and ovoids (O) with the original needle (ND) positions (DMBT + O + ND) and another with the DMBT T&O and spatially reoptimized needles (OptN) positions (DMBT + O + OptN). All retrospectively reoptimized plans have been compared to the original plan (OP) as well. The accuracy of 3D printing was verified through the image registration between the planning CT and the CT of the 3D-printed template. The average difference in D2cc for the bladder, rectum, and sigmoid between the OPs and DMBT + O + OptNs were −8.03 ± 4.04%, −18.67 ± 5.07%, and −26.53 ± 4.85%, respectively. In addition, these average differences between the DMBT + O + ND and DMBT + O + OptNs were −2.55 ± 1.87%, −10.70 ± 3.45%, and −22.03 ± 6.01%, respectively. The benefits could be significant for the patients in terms of target coverage and normal tissue sparing and increase the optimality over free-hand needle positioning.

Verified
Journal Article
Open access
PDF file
RHRobert Hawranko
Robert Hawranko
JSJames J. Sohn
James J. Sohn
KNKeith Neiderer
Keith Neiderer
EBEd Bump
Ed Bump
THTimothy Harris
Timothy Harris
WSWilliam Song
William Song
This study investigates plan quality generated by an MR-Linac (MRL) treatment planning system (TPS) for 5-fraction stereotactic body radiation therapy (SBRT) of primary pancreatic cancer (PCa). In addition, an isotoxic dose escalation was investigated with the MRL TPS based on stereotactic MR-guided adaptive radiation therapy (SMART) trial constraints. A clinical workflow was developed for adaptive and non-adaptive treatments with the MRL, on which a time-driven activity-based costing (TDABC) analysis was performed to quantify clinical efficacy. Fifteen PCa patients previously treated with a conventional Linac were retrospectively re-planned for this study. Three plans were generated for each patient using the original prescription dose (PD) and organ at risk (OAR) constraints (Plan 1), following SMART trial’s OAR constraints but with the original PD (Plan 2), starting with Plan 2, following an isotoxic dose escalation strategy where the dose was escalated until any one of the SMART trial’s OAR constraints reached its limit (Plan 3). Conformity index (CI) and the ratio of the 50% isodose volume to PTV (R50%) conformity metrics were calculated for all 45 MRL plans, in addition to standard dose-volume indices. Forty-five MRL plans were created which met their respective dosimetric criteria described above. For Plan 1, the MRL TPS successfully achieved equivalent or lower OAR doses while maintaining the prescribed PTV coverage for the 15 plans. A maximum dose to the small bowel was reduced on average by 4.97 Gy (range: 1.11–10.58 Gy). For Plan 2, the MRL TPS successfully met all SMART trial OAR constraints while maintaining equivalent PTV coverage. For Plan 3, the MRL TPS was able to escalate the prescription dose from the original 25–33 Gy by, on average, 36 Gy (range: 15–70 Gy), and dose to the PTV was successfully escalated to at least 50 Gy for all 15 plans. These achievements were made possible, in part, due to the omission of the ITV afforded by the MRL’s real-time target tracking technology and sharper dose penumbra due to its unique dual-focus MLC design. The 0.35T MRL TPS can generate plans that are equivalent to conventional Linac-based plans for SBRT of PCa. Through analyzing Plan 2 and 3 strategies, and due to the real-time target localization capabilities of the MRL system, increased OAR sparing and/or target dose escalation are possible.

15 November 2024 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
SGSuman Gautam
Suman Gautam
AOAlexander F. I. Osman
Alexander F. I. Osman
DRDylan Richeson
Dylan Richeson
SGSomayeh Gholami
Somayeh Gholami
BMBinod Manandhar
Binod Manandhar
WSWilliam Song
William Song
Background: Formulating a clinically acceptable plan within the time‐constrained clinical setting of brachytherapy poses challenges to clinicians. Deep learning based dose prediction methods have shown favorable solutions for enhancing efficiency, but development has primarily been on external beam radiation therapy. Thus, there is a need for translation to brachytherapy.Purpose: This study proposes a dose prediction model utilizing an attention‐gating mechanism and a 3D UNET for cervical cancer high‐dose‐rate intracavitary brachytherapy treatment planning with tandem‐and‐ovoid/ring applicators.Methods: A multi‐institutional data set consisting of 77 retrospective clinical brachytherapy plans was utilized in this study. The data were preprocessed and augmented to increase the number of plans to 252. A 3D UNET architecture with attention gates was constructed and trained for mapping the contour information to dose distribution. The trained model was evaluated on a testing data set using various metrics, including dose statistics and dose‐volume indices. We also trained a baseline UNET model for a fair comparison.Results: The attention‐gated 3D UNET model exhibited competitive accuracy in predicting dose distributions similar to the ground truth. The average values of the mean absolute errors were 0.46 ± 11.71 Gy (vs. 0.47 ± 9.16 Gy for a baseline UNET) in CTVHR, 0.55 ± 0.67 Gy (vs. 0.70 ± 1.54 Gy for a baseline UNET) in bladder, 0.42 ± 0.46 Gy (vs. 0.49 ± 1.34 Gy for a baseline UNET) in rectum, and 0.31 ± 0.65 Gy (vs. 0.20 ± 3.76 Gy for a baseline UNET) in sigmoid. Our results showed that the mean individual differences in ΔD2cc for bladder, rectum, and sigmoid were 0.38 ± 1.19 (p = 0.50), 0.43 ± 0.71 (p = 0.41), and −0.47 ± 0.79 (p = 0.30) Gy, respectively. Similarly, the mean individual differences in ΔD1cc for bladder, rectum, and sigmoid were 0.09 ± 1.21 (p = 0.36), 0.20 ± 0.95 (p = 0.24), and −0.21 ± 0.59 (p = 0.30) Gy. The mean individual differences for ΔD90, ΔV100%, ΔV150%, and ΔV200% of the CTVHR were −0.45 ± 2.42 (p = 0.26) Gy, 0.55 ± 9.42% (p = 0.78), 0.82 ± 4.21% (p = 0.81), and −0.80 ± 10.48% (p = 0.36), respectively. The model requires less than 5 s to predict a full 3D dose distribution for a new patient plan.Conclusion: Attention‐gated 3D UNET revealed a promising capability in predicting voxel‐wise dose distributions compared to 3D UNET. This model could be deployed for clinical use to predict 3D dose distributions for near real‐time decision‐making before planning, quality assurance, and guiding future automated planning, making the current workflow more efficient.